ClinicalTrials.gg

Cataract clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,632 studies for Cataract across more than 10 countries. 235 are recruiting or about to start. 1,345 of them are mainly about Cataract (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its narrower condition Capsule Opacification too: 1,651 studies, 236 open.

ClinicalTrials.gov finds 1,995 studies for Cataract. How that becomes 1,627 here

This page counts the studies the registry files under Cataract, and those it files under no condition that list Cataractthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,995Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −12Filed under a narrower condition, counted on its own pageCapsule Opacification 7
  3. −108List Cataract as a condition, but the registry did not file them under itMost often written as “Cataract Surgery” (29), “Congenital Cataract” (13), and “Cataract Senile” (12). The registry filed them under other conditions only, most often Dry Eye Syndromes (10) and Anxiety Disorders (9).
  4. −248Match it another way218 name it in the title, 24 in a keyword, and 6 by a synonym or other text the search reads.
  5. 1,627The count on this page214 of them list Cataract in their own words; the registry filed them under no condition.

Status

Completed
1,024
Status unknown
216
Recruiting
142
Not yet recruiting
78
Terminated
66
Withdrawn
50

Phase

Phase 4
174
Phase 3
106
Phase 2
54
Phase 1
30
Early Phase 1
5

Where

United States
456
China
183
Austria
115
France
67
Spain
61
Germany
61

Who develops what

Add Cataract to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 8 programs from 6 companies, 6 with this as their studies’ main aim; 3 with a live phase 3 study; 3 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
TimololRecent, repeated
Evidence
  • NCT07218796 · SpyGlass Pharma, Inc. · Phase 3 · live · comparator · “Timolol Maleate Ophthalmic Solution, 0.5%” · registered Oct 2025
  • NCT07218783 · SpyGlass Pharma, Inc. · Phase 3 · live · comparator · “Timolol Maleate Ophthalmic Solution, 0.5%” · registered Oct 2025
  • NCT07036510 · EyeD Pharma · Phase 2 · live · comparator · “Timolol eye drops 0.5%” · registered Jun 2025
  • NCT06120842 · SpyGlass Pharma, Inc. · Phase 2 · live · comparator · “Timolol Maleate Ophthalmic Solution, 0.5%” · registered Nov 2023
AbbVie30% of its industry studiesUS: off-patent, 43 generics marketed24 studies

8 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
Bimatoprost Implant System☆ Track2 live phase-3 studies: NCT07218796, NCT07218783SpyGlass Pharma, Inc.
MoxifloxacinApproved: US☆ Track1 live phase-3 study: NCT07305987Laboratorios Sophia S.A de C.V.
DexamethasoneApproved: US · EU 2016☆ Track1 live phase-3 study: NCT07305987Laboratorios Sophia S.A de C.V.

The 3 in phase 3 with the nearest primary completion, of 8 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 31 Dec 2026 est.Triamcinolone · Research Insight LLC · Phase 4 main aimNCT07276802 The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery) — primary endpoint: Primary · 40 enrolled
  • Jan 2027 est.Drugs, Investigational · EyeD Pharma · Phase 2 named, not the main aimvs TimololNCT07036510 Safety and Efficacy of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract Surgery — primary endpoint: Stage 1: Number (%) of participants experiencing adverse events · 42 enrolled
  • Feb 2027 est.0.4% ZOC2017217 · Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd. · Phase 2 main aimNCT07395986 A Multicenter, Randomized, Double-Masked, Placebo-Controlled Pilot Study to Evaluate the Efficacy and Safety of ZOC2017217 in Subjects With Age-Related Cataract — primary endpoint: BCDVA · 8 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Cataract studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Angiogenesis inhibitors 1 open · Opioids 1 open · Corticosteroids 44 · NSAIDs 15 · Antimuscarinics 3

Coming up

68studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Who these studies take

Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger. 10 (7%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 16 (11%) take healthy volunteers.

Recruiting studies that take each age, of 142
AgeWomenMen
1010 (7%)10 (7%)
1868 (48%)68 (48%)
3096 (68%)96 (68%)
40113 (80%)113 (80%)
50133 (94%)133 (94%)
65140 (99%)140 (99%)
75139 (98%)139 (98%)
85122 (86%)122 (86%)

Across all 1,632 studies, recruiting or not: 10% stop at 75 or younger and 6% at 65; 12% take children; <1% are for women only and <1% for men only; 20% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Cataract studies take

Of 46 phase 4 interventional studies under Cataract, half reached primary completion within 20 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 313 mo9–38 · 31 studies11 mo9–15 · 23 studies—
Phase 420 mo11–34 · 46 studies—22 mo11–39 · 39 studies
Interventional, no phase17 mo9–29 · 493 studies16 mo10–28 · 190 studies18 mo7–30 · 303 studies
Observational16 mo9–30 · 235 studies13 mo8–35 · 67 studies19 mo9–30 · 168 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Stopped1

Newly registered12

Show 7 more

Studies

Recruiting first, then most recently updated. Showing 50 of 1,632. Browse all 1,632 → or search them.